Phase I Clinical Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of LYN101

This is a Phase 1, two-part, first-in-human, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of a single dose of LYN101 in healthy subjects (part A) and multiple doses in postmenopausal women with low bone mass (part B).

NCT Number	NCT07178327
Lead Sponsor	Shanghai TTM-Bio Technology Co., Ltd
Conditions	Osteoporotic Fracture
Enrollment	44 participants
Start Date	2025-09-06
Primary Completion	2026-09-06 (estimated)
Study Completion	2027-09-06 (estimated)
Updated on ClinicalTrials.gov	2025-09-17